For example, while ER is currently the only biomarker guiding endocrine treatment in breast cancer, the discovery of ESR1 mutations and their prediction of treatment resistance will probably play an increasing role in treatment decisions30, 31. The gene discussed is ESR1; the disease is breast carcinoma.